Table 5.

The Comparison With the Other Clinical Study of Oxaliplatin Based Regimen as Adjuvant Chemotherapy

	CapOX		mFOLFOX6
Hospital visits	Every 3 weeks		Every 2 weeks
Port-catheter	Not require		Require
	Our study	XELOXA	MOSAIC	JOIN
Dose intensity
Oxaliplatin	76.5%	87.0%	>80.0%	78.2%
Capesitabine	75.8%	84.0%	–	–
5-FU	–	–	84.4%	87.7% (bolus), 78.1% (infusion)
Treatment completion	82.9%	69.0%	74.7%	67.0%
DFS rate	63.8% (five-year)	66.1% (five-year)	73.3% (five-year)	–
OS rate	71.0% (five-year)	77.6% (five-year)	78.5% (six-year)	–
HFS (>grade 3)	0%	5.0%	–	–
PSN (>grade 3)	17.1%	9.0%	12.4%	5.8%

HFS, hand–foot syndrome; PSN, peripheral sensory neuropathy.